Essential Tremor – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Essential Tremor – Pipeline Review, H2 2016’, provides an overview of the Essential Tremor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Essential Tremor

The report reviews pipeline therapeutics for Essential Tremor by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Essential Tremor therapeutics and enlists all their major and minor projects

The report assesses Essential Tremor therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Essential Tremor

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Essential Tremor

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Essential Tremor pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Merz Pharma GmbH & Co KgaA

Neurocrine Biosciences Inc

Sage Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Essential Tremor Overview 6

Therapeutics Development 7

Pipeline Products for Essential Tremor - Overview 7

Essential Tremor - Therapeutics under Development by Companies 8

Essential Tremor - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Essential Tremor - Products under Development by Companies 11

Essential Tremor - Companies Involved in Therapeutics Development 12

Merz Pharma GmbH & Co KgaA 12

Neurocrine Biosciences Inc 13

Sage Therapeutics Inc 14

Essential Tremor - Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 24

incobotulinumtoxin A - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

NBI-640756 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

SAGE-217 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

sepranolone - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Essential Tremor - Dormant Projects 40

Essential Tremor - Discontinued Products 41

Essential Tremor - Product Development Milestones 42

Featured News & Press Releases 42

Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting 42

Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 43

Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor 44

Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Essential Tremor, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Essential Tremor – Pipeline by Merz Pharma GmbH & Co KgaA, H2 2016 12

Essential Tremor – Pipeline by Neurocrine Biosciences Inc, H2 2016 13

Essential Tremor – Pipeline by Sage Therapeutics Inc, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Essential Tremor – Dormant Projects, H2 2016 40

Essential Tremor – Discontinued Products, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for Essential Tremor, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Targets, H2 2016 16

Number of Products by Stage and Targets, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports